Literature DB >> 10989829

Chemotherapy in advanced nasopharyngeal cancer.

H Ali1, M al-Sarraf.   

Abstract

Chemotherapy is an integral part of treatment for patients with nasopharyngeal carcinoma. Chemotherapy can achieve long-term survival rates of up to 15% to 20%, even in patients with recurrent or metastatic disease. In the majority of studies reported, patients with previously untreated locally advanced stage III and IV nasopharyngeal carcinoma showed improved local control, decreased systemic metastasis, and improved disease-free and overall survival when treated with cisplatin (Platinol)-based combination chemotherapy in conjunction with radiotherapy. In prospective, randomized, phase III trials, concurrent chemoradiotherapy, followed by adjuvant chemotherapy, significantly improved local control, systemic control, and progression-free and overall survival. The authors believe that different sequences of treatment modalities and newer chemotherapy agents need to be investigated in the future.

Entities:  

Mesh:

Year:  2000        PMID: 10989829

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  13 in total

1.  Radiation therapy combined with (or without) cisplatin-based chemotherapy for patients with nasopharyngeal cancer: 15-years experience of a single institution in Korea.

Authors:  Yeon-Sil Kim; Bum-Soo Kim; So-Lyoung Jung; Yeon-Soo Lee; Min-Sik Kim; Dong-Il Sun; Eun-Jung Yoo; Seong-Kwon Mun; Sei-Chul Yoon; Su-Mi Chung; Hoon-Kyo Kim; Seung-Ho Jo; Jin-Hyoung Kang
Journal:  Cancer Res Treat       Date:  2008-12-31       Impact factor: 4.679

2.  Large retropharyngeal abscess: a case of mistaken identity.

Authors:  N Makaram; R Gohil; Q Gardiner; J Manickavasagam
Journal:  BMJ Case Rep       Date:  2016-09-16

3.  Betulinic acid induces Bax/Bak-independent cytochrome c release in human nasopharyngeal carcinoma cells.

Authors:  Yang Liu; Wenlong Luo
Journal:  Mol Cells       Date:  2012-04-17       Impact factor: 5.034

4.  Conventional 2D (2DRT) and 3D conformal radiotherapy (3DCRT) versus intensity-modulated radiotherapy (IMRT) for nasopharyngeal cancer treatment.

Authors:  Francesco Moretto; Monica Rampino; Fernando Munoz; Maria Grazia Ruo Redda; Alessia Reali; Vittoria Balcet; Serena Badellino; Cristina Piva; Marina Schena; Mario Airoldi; Oliviero Ostellino; Giancarlo Pecorari; Riccardo Ragona; Umberto Ricardi
Journal:  Radiol Med       Date:  2014-01-15       Impact factor: 3.469

Review 5.  Locally advanced nasopharyngeal cancer.

Authors:  J F Ensley; E Youssef; H Kim; G Yoo
Journal:  Curr Treat Options Oncol       Date:  2001-02

6.  Nasopharyngeal carcinoma in adolescents: a retrospective review of 42 patients.

Authors:  Said Afqir; Nabil Ismaili; Khaoula Alaoui; Samir Ahid; Jean-Pierre Lotz; Elizabeth Horn; Touria Bouhafa; Redouane Abouqal; Hassan Errihani
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-01-22       Impact factor: 2.503

Review 7.  Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma.

Authors:  B Baujat; H Audry; J Bourhis; A T C Chan; H Onat; D T T Chua; D L W Kwong; M Al-Sarraf; K H Chi; M Hareyama; S F Leung; K Thephamongkhol; J P Pignon
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

8.  c-Jun NH2-terminal kinase activation is essential for up-regulation of LC3 during ceramide-induced autophagy in human nasopharyngeal carcinoma cells.

Authors:  Ting Sun; DanDan Li; Linlin Wang; LiangPing Xia; JianGuo Ma; Zhong Guan; GongKan Feng; XiaoFeng Zhu
Journal:  J Transl Med       Date:  2011-09-26       Impact factor: 5.531

9.  Locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy plus concurrent weekly cisplatin with or without neoadjuvant chemotherapy.

Authors:  Chan Woo Wee; Bhumsuk Keam; Dae Seog Heo; Myung-Whun Sung; Tae-Bin Won; Hong-Gyun Wu
Journal:  Radiat Oncol J       Date:  2015-06-30

Review 10.  Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma.

Authors:  Susanna Hilda Hutajulu; Johan Kurnianda; I Bing Tan; Jaap M Middeldorp
Journal:  Ther Clin Risk Manag       Date:  2014-09-05       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.